A Phase 1b, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects with WHO Group 1 Pulmonary Arterial Hypertension
TP82. TP082 LET IT BE - CLINICAL ADVANCES IN PULMONARY VASCULAR DISEASE: PAH AND BEYOND | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A3602-A3602
10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3602